Biotricity

Biotricity Inc. (OTC: BTCY) is a medical technology company focused on the development and commercialization of bio-sensing remote patient monitoring solutions for cardiac health applications. According to its website at biotricity.com, the company has developed the Bioflux cardiac monitoring system — a remote cardiac monitoring platform that enables physicians to monitor patients' heart rhythms continuously outside of clinical settings, capturing arrhythmia and other cardiac events in the patient's everyday environment where symptoms are most likely to occur. Biotricity's remote cardiac monitoring platform is designed to improve the diagnostic accuracy of cardiac monitoring compared to traditional short-term Holter monitors, providing clinicians with extended monitoring periods and real-time data transmission that enables timely clinical intervention when significant cardiac events are detected.

Biotricity's Bioflux monitoring system, described at biotricity.com, consists of a patient-worn monitoring device that continuously records cardiac rhythm data and wirelessly transmits this data in real time to Biotricity's cloud-based platform, where it is analyzed by the company's cardiac monitoring center and reviewed by qualified cardiac technicians who identify clinically significant events and transmit reports to the prescribing physician. This real-time cardiac monitoring and reporting service — known as Mobile Cardiac Telemetry — provides higher clinical sensitivity for detecting intermittent arrhythmias than traditional event monitors or Holter monitors that require patients to trigger recording when they experience symptoms. Biotricity's monitoring services are reimbursable under existing cardiac monitoring CPT codes, providing a clear revenue pathway through established healthcare billing infrastructure.

Biotricity is building its commercial presence in the remote cardiac monitoring market through direct sales relationships with cardiologists, electrophysiologists, and primary care physicians who prescribe extended cardiac monitoring for patients with palpitations, syncope, atrial fibrillation, and other cardiac symptoms. According to biotricity.com, the company differentiates its Bioflux platform through its real-time monitoring capabilities, high-quality electrode design that improves patient comfort and signal quality, and responsive customer service to both prescribing physicians and their patients. Biotricity's remote patient monitoring focus positions it at the intersection of the rapidly growing cardiac monitoring market and the broader telehealth and remote patient monitoring trend that has accelerated significantly as healthcare systems have embraced digital health technologies.